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Abstract
Background: The epidermal growth factor receptor (EGFR) mutation status assessment has become increasingly
important given the significant impact of tyrosine kinase inhibitors in lung cancer management.
Our aim was to compare real life operational characteristics for three EGFR mutation assays - two targeted
approaches and a next generation sequencing (NGS) technique.
Methods: EGFR mutation status was assessed for lung adenocarcinoma samples (formalin fixed- paraffin embedded
samples) using qPCR, SNaPshot and NGS (Ion Torrent™) techniques.
Results: A total of 15 high clinical significance mutations were identified by at least one technique from the total
of 64 samples. All mutations were identified by the TaqMan qPCR technique while SNaPshot in conjunction with
fragment analysis identified 11 EGFR mutations. The NGS approach followed by an automatic analysis using the
default calling parameters identified 10 mutations from the SNaPshot/qPCR panel and other three insertions, five
point mutations and 58 silent variants; manual data review identified all 15 high significance mutations.
Conclusions: Performance was similar for high tumor content samples but careful data analysis and post hoc variant
calling filter alterations were necessary in order to obtain robust results from low tumor content samples by NGS. NGS
is able to generate a comprehensive mutational profile albeit at a higher cost and workload. Result interpretation
should take into account not only general run parameters such as mean read depth but also relative coverage and
read distribution; currently there is an acute need to define firm recommendations/standards concerning NGS data
interpretation and quality control.
Background
Epidermal growth factor receptor (EGFR) mutation status
is regarded as a particularly important element for improv-
ing non squamous non-small cell lung cancer (NSCLC)
prognosis. EGFR mutations were reported with a frequency
of around 10 % for total lung adenocarcinoma but up to
40 % in some Asian cohorts – mainly represented by exon
19 deletions and one exon 21 point substitution c.2369C >
T (L858R) [1, 2]. Both lead to ligand-independent activation
of the tyrosine kinase domain and confer sensitivity to
EGFR tyrosine kinase inhibitors (TKIs). Other mutations
were reported in less than 5 % of total cases - mainly point
mutations G719X [3],T783A,V765A [4], and exon 20 inser-
tions; despite low incidence they are assessed on a regular
basis as some have been linked to response to EGFR TKIs.
Mutation status can be determined by either targeted
approaches or direct sequencing. Targeted approaches are
used to detect a limited number of clinically significant
mutations – usually therapy response predictors. These
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methods have higher sensitivity than Sanger sequencing
and may reliably be used for small biopsy or cytology sam-
ples (with down to 1 % tumor cells content) [5].
Sequencing techniques have the main advantage of being
able to identify all mutations in the studied region (previ-
ously known or not); main drawbacks are generally a higher
workload and variable sensitivity – samples with tumor
cells content over 20 % being usually required at least for
Sanger technique. [6].
Currently there is no consensus on the optimal approach
and existing guidelines do not strongly favor one method in
particular.
Our aim was to compare real life operational charac-
teristics for three EGFR mutation assays - two targeted
approaches and a next generation sequencing (NGS)
technique.
Methods
Lung adenocarcinoma samples addressed for routine
EGFR testing to the local molecular diagnostic laboratory
between October 2013 and June 2015 were considered.
Selection was based on availability of a previously signed
informed consent allowing for biopsy samples banking
and future research usage and availability of sufficient
biological material without compromising further analyses
if necessary.
Samples were anonymized prior to processing. Study
protocol was reviewed and approved by the University
of Medicine and Pharmacy “Grigore T. Popa” Iasi Ethics
Commission (the 4th of August 2015).
Tissue samples were mainly obtained from primary
tumors; there was one pleural fluid sample. Every sample
was reviewed and tumor cell percentage was estimated by
pathologists prior to DNA extraction; macro-dissection
was performed if deemed necessary to increase tumor cell
content.
Each sample underwent genomic DNA extraction
using the Macherey Nagel FFPE DNA kit according to
manufacturer specifications. DNA quality and quantity
were assessed on an Eppendorf BioPhotometer Plus
using a Helma Tray cell with 1 mm light path lid. EGFR
mutation status was assessed using three independent
methods – quantitative PCR (qPCR), SNaPshot assay,
NGS.
For the primer extension reaction (SNaPshot) a multi-
plex PCR (GoTaq G2 Hot Start, Promega, Madison, WI,
USA) was performed on 50 ng extracted DNA using
primers and conditions from Table 1 [7]. PCR products
were visualized by agarose gel electrophoresis to confirm
correct amplification followed by enzymatic purification.
Then one step extension was conducted following manu-
facturers recommendations and products were run on ABI
PRISM 310 Genetic Analyzer (Life Technologies/Applied
Biosystems, Foster City, CA, USA). EGFR exon 19 dele-
tions were assessed using the method described by Pan et
al. [8]. Data analysis was performed with GeneMapper
Table 1 Primer sequences and cycling details for multiplex PCR and SNaPshot
Primer Primer sequence Amplification conditions
Multiplex PCR - Primers and Cycling Conditions
EGFR Ex 18 FWD 5′- CCCCCCCAGCTTGTGG -3′ 95OC - 3 min
45 cycles of:
94OC - 30 s
63OC - 90 s
72OC - 90 s
Final extension
72OC - 10 min
4 OC - end
EGFR Ex 18 REV 5′- ACCGTGCCGAACGCAC -3′
EGFR Ex 20 FWD 5′- CTCTCCCTCCCTCCAGGAAG -3′
EGFR Ex 20 REV 5′- TTCCCGGACATAGTCCAGGA -3′
EGFR Ex 21 FWD 5′- CGCAGCATGTCAAGATCACAG -3′
EGFR Ex 21 REV 5′- TGGCTGACCTAAAGCCACCT -3′
SNaPShot Assay - Primers and Cycling Conditions
EGFR-2155R 5′- TGGTTAGATGGAACGCACCGGAGC -3′ 96OC - 10 s
25 cycles of:
50OC 5 s
60OC - 30 s
Final:
4OC - ∞ min
EGFR-2156R 5′- TAGATGTGGTTAGATGCGAACGCACCGGAG -3′
EGFR-2369R 5′- TGGTTAGATGTGGTTAGATGGAAGGGCATGAGCTGC -3′
EGFR-2573 F 5′- ATGTGGTTAGATGTGGTTAGATGAAGATCACAGATTTTGGGC -3′
EGFR-2582 F 5′- GATGTGGTTAGATGTGGTTAGATGTGGTTAGATGTGGGCTGGCCAAAC -3′
Sizing Assay - Primers and Cycling conditions
EGFR Ex19 FWD 5′ - GCACCATCTCACAATTGCCAGTTA-3 98OC - 3 min
45 cycles of:
98OC - 30 s
60OC - 60 s
72OC - 60 s
Final extention:
72OC 10 min
4OC - ∞ min
EGFR Ex19 REV 5′-/6FAM/AAAAGGTGGGCCTGAGGTTCA-3)
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Analysis Software version 4.0 (Life Technologies/Applied
Biosystems) using the automatic calling parameters.
Quantitative PCR was performed using the EGFR Entro-
gen® kit on an AB 7500 Real-Time PCR system following
manufacturer instructions. This kit usually requires 80 ng
extracted DNA being able to detect 29 mutations: 19 differ-
ent exon 19 deletions, exon 18 mutations (G719X) and 3
exon 20 insertions, c.2361G >A (T790M), c.2369C >T
(L858R), c.2582 T >A (L861Q), c.2303G >T (S768I).
Targeted NGS was performed on an Ion Torrent plat-
form using the Ion AmpliSeq Cancer Hotspot Panel v2
(both from Life Technologies). Briefly, DNA amplification
started from 10 ng of extracted DNA followed by barcode
library construction using the Ion Ampliseq Library Kit 2.0
(Life Technologies). Following quantification, libraries were
equalized at 100 pM, attached and amplified on Ion Sphere
Particles. Sequencing was performed using PGM seq 200
kit v2 or PGM Hi-Q kit by pooling 6-8 libraries on an Ion
316 chip v2 and 10 - 11 libraries on an Ion 318 chip v2
according to manufacturer’s protocol. Aimed read depth
was 1000×.
Sequence readings were aligned against the hg19 hu-
man genome, reference sequence NM_005228.3, using
the default alignment settings (Ion Torrent Suite Software v
4.6). Data was analyzed using SEQUENCE Pilot module
SeqNext v 4.2.0 (JSI Medical System); only EGFR data were
considered; variant frequency threshold was set to 5 % with
a minimum of 5 readings per strand for the automatic ana-
lysis as is recommended for AmpliSeq [9]; automatic calling
was followed by manual review.
Price estimates were based on consumables cost alone;
manpower costs were set aside as these figures may signifi-
cantly differ between countries and settings (ex. clinical
versus clinical research versus academic research). For NGS
additional sample reruns (mainly for low coverage issues)
were considered in the final estimate.
Numeric data is presented as mean +/- standard
deviation.
Results
Study pool contained 64 samples from 41 male and 23
female lung cancer patients; mean age was 62 +/- 9 years.
All samples were formalin-fixed paraffin-embedded
(FFPE) - 36 were obtained from surgical specimens, 26
from small specimens (25 bronchial biopsies and one
transthoracic core biopsy sample). There were two cyto-
logical samples - pleural fluid and transbronchial fine
needle aspirate (upper lobe mass) cytoblocks. Macrodis-
section was deemed necessary and performed for 17
samples, nine being surgical specimens. Final estimated
tumor cell percentage ranged between 1 and 75 % (mean
31 +/- 25 %).
Extracted DNA quantity was similar for both surgical
and bronchial biopsies (8.7 +/- 9.1 ng/μl vs 7.1 +/- 7.1 ng/
μl) despite larger volume and higher percentage of tumor
cells per section for surgical samples (43 +/- 24 % vs 18 +/-
17 %). DNA quality estimated by the 260/280 ratio was
1.66 +/-0.28.
Quality control for NGS technique showed a mean
mapped sequences of 312986 reads per sample and a mean
read length of 105 +/- 7 bp. Average mean read depth was
1265 +/- 637× with a median of 1204× and interquartile
range of 845 – 1680 × .
A total of 15 high clinical significance mutations were
identified by at least one technique from a total of 14 sam-
ples. All mutations were identified by the TaqMan qPCR
technique while SNaPshot in conjunction with fragment
analysis identified 11 EGFR mutations (10 samples); one
sample harbored two mutations - c.2369C >T (L858R) and
c.2361G >A (T790M).
A comprehensive view of EGFR mutation spectrum is
showed in Table 2.
The NGS approach followed by an automatic analysis
using the default 5 % variant frequency/5× variant coverage
threshold allowed the identification of only 10 mutations
from the SNaPshot/qPCR panel. The other five mutations
were present in the NGS readings failing to reach the
default calling thresholds - Table 3 but were picked out by
manual reviewing known hotspots. Globally while the
mutations identified using default variant calling parame-
ters had an average mean read depth of 723 +/- 312× the
missed five mutations had a mean coverage of 576 +/-398×.
However the NGS identified other sequence variations:
three insertions (c.2310_2311insCAC, c.2317_2319dup-
CAC, c.2315_2320dupCCCACG), five point mutations
c.2327G > A (R776H), c.2125G > A (E709K), c.2260A > C
(K754Q), c.2185G > A (G729R), c.2279 T > C (L760P).
There were also 58 silent variants -54 c.2361G > A
(Q787Q), and one of each: c.339C > T (Y113Y), c.876G >
A (V292V), c.2430C > T (G810G), c.2319C > T (H773H).
An estimate of workload and costs are shown in Table 4
– initial DNA extraction not included (around 5 man
hours workload and 24 h for final DNA solution at a cost
of 10 euros/sample).
Discussion
Nowadays EGFR mutation assessment has become the
standard approach in non-small cell lung cancer manage-
ment and is available in most countries. There are many
techniques available but there is no strong consensus on
optimum approach and further complications may arise
from the need for simultaneous multiple target testing
(such as larger DNA quantities).
Presently EGFR mutation testing relies on amplifica-
tion/sequencing approaches while other actionable ab-
normalities such as the EML4-ALK translocations are
usually detected by fluorescence in situ hybridization or im-
munohistochemical analysis [10]. More targets are expected
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to become relevant as new drugs emerge (PI3K) [11, 12] or
existing ones expand their initial indications (BRAF, HER2)
[13, 14]. Considering these developments the need for not
only precise and sensitive but also cost effective and scal-
able detection methods becomes acute as some of these
mutations affect less than 1 % from the NSCLC patients.
False negative results may occur as a consequence to
poor quality samples or faulty technique implementations
but also due to the intrinsic limitations of each technique;
post-analytical data interpretation should take into ac-
count these inherent limitations. This is especially relevant
to NGS approaches as results depend on a long chain of
serial technical steps and therefore multiple check-points
should be implemented, each one with specific minimal
quality parameters.
The aim of our study was to compare three widely avail-
able detection methods in order to identify potential
causes for discordant results and to define minimal quality
parameters that need to be attained for a high confidence
result.
Our data suggest that all three methods return concord-
ant results for high tumor cell content samples (over 15 %);
for these samples qPCR and SNaPshot were implemented
without any particular technical difficulty and for NGS a
minimum mean coverage of 300× proved sufficient to de-
tect relevant mutations.
Differences emerged when low tumor cell content
samples were considered (25 samples - 39 % of total
samples) with a mean tumor content of 5.9 % +/- 3.8 %.
– SNaPshot approach failed to detect four mutations out
Table 3 NGS run metrics for false negative results samples














BM 65 L858R 1039 435 0.41 4.6 20 10 5.05
BM 76 DEL19 891 1028 1.15 2.9 29 2 22.9
BM 145 DEL19 36 2 0.05 100 2 14 4.91
BM 159 L858R 480 322 0.66 2.2 7 3 11.9
BM 160 L858R 436 299 0.68 4.4 13 5 0.22





DNA change Designation Total Coverage (%, number of reads)
BM 40 60 T790M T790M c.2369C > T, T790M, 40 % (141),
L858R L858R c.2573 T > G L858R 23 % (60)
BM 49 25 L858R L858R c.2573 T > G L858R 38 % (321)
BM 65 10 L858R none Not detected by automatic analysis
BM 71 6 DEL 19 DEL 19 c.2236_2250delGAATTAAGAGAAGCA delELREA 73 % (2467)
BM 72 40 L858R L858R c.2573 T > G L858R 61 % (554)
BM 75 48 G719X G719X c.2155G > A, G719S, 24 % (63),
c.2327G > A R776H, 58 % (28),
BM 76 2 DEL 19 none Not detected by automatic analysis
BM 82 24 L858R L858R c.2573 T > G L858R 25 % (129)
BM 101 4 DEL 19 DEL 19 c.2185G > A G729R, 6 % (10),
c.2235_2249delGGAATTAAGAGAAGC delKELREA, 26 % (48),
c.2260A > C K754Q, 27 % (50),
c.2279 T > C L760P, 6 % (11),
BM 145 14 DEL 19 DEL 19 Not detected by automatic analysis
BM 150 56 DEL 19 DEL 19 Not detected by automatic analysis
BM 157 72 L858R L858R c.2573 T > G, L858R 74 % (792),
BM 159 3 L858R none Not detected by automatic analysis
c.2125G > A, E709K, 7 % (36),
BM 160 5 L858R none Not detected by automatic analysis
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of seven. NGS approach required careful data analysis
and post hoc variant calling filter for five low tumor cell
content samples. These results are consistent with pub-
lished data supporting tumor cell content sensitivity
thresholds – around 1 % for qPCR [15], 10 % for SNap-
Shot [16] and 5–20 % for IonTorrent depending on
sample type [9] This may be particularly important as
real life medical practice increasingly relies on minimally
invasive diagnostic approaches - as it is the case for
EBUS-TBNA or other techniques that usually provide
small core or cytology samples [5]. Macro-dissection
may improve tumor cell content but still requires the
presence of large enough tumor spots. Microdissection
may yield better results but require specific equipment
and may significantly add to workload and total cost as
skilled manpower and specific equipment that are usu-
ally expensive. Although our data showed no difference
between bronchial biopsies and surgical specimens in
terms of tumor cell percentage it should be noted that
banked and standard practice biopsy specimens may dif-
fer in terms of tissue quality.
Despite NGS high overall mean coverage, read quality
and uniform read distribution there were some cases re-
quiring careful data consideration. Extracted DNA quality
may explain one false negative result - one sample with low
mean coverage (36×) despite a 14 % tumor cell content.
This was probably due to higher DNA fragmentation (only
62 bp mean read length [17]. Four false negative results
were generated by using the default variant frequency
threshold of 5 %. While this threshold is useful to filter out
erroneous variant calls it should be cautiously applied to
known hotspots at least for low coverage and/or low quality
samples. For these positions high sensitivity should prob-
ably be prioritized over positive predictive power possibly
by implementing an adaptive variant caller strategy taking
into account tumor cells content and allowing for intra
tumor molecular heterogeneity. In these cases a second
approach (for ex qPCR) may be necessary in order to con-
firm results before validating the data for clinical use.
Effective NGS implementation requires good quality
DNA preferably from a tumor rich sample, careful ampli-
fication and library construction, and careful post analytic
data interpretation. Moreover according to our experience
around 10 % of samples required additional runs and 2 %
of the NGS libraries were recreated due to low coverage.
Despite these constraints the NGS approach returned
richer data due to massive parallel analysis power and
various additional sequence variations were identified, in-
cluding five rare point mutations - c.2327G > A (R776H),
c.2125G > A (E709K), c.2260A > C (K754Q), c.2185G >A
(G729R), c.2279 T > C (L760P).
There is little information available on c.2327G >A
(R776H) mutation clinical significance and mainly from
single case reports. Apparently c.2327G >A mutations may
occur as germline variants [18] and may be associated to
squamous differentiation [19]. Our case associated the
c.2327G >A and c.2155G>A (G719S) mutations - an inter-
esting occurrence given the low individual frequency for
each. This association has been previously reported as
retaining in vitro sensitivity to gefitinib and erlotinib [20].
The c.2125G>A (E709K) substitution is not a frequent
occurrence and has been associated to tyrosine kinase in-
hibitors sensibility (TKI) [4]; response may be less favorable
when compared to exon 19 and 21 mutations [21].
The c.2185G >A (G729R) has been reported in lung
adenocarcinoma individual cases [22] and G729E in head
and neck squamous cell carcinoma [23]; available results
mentioned progressive disease.
Similarly the c.2279 T > C (L760P) substitution has been
mentioned as an unique finding in a case report of a lung
adenocarcinoma patient of Asian descent [24]; there was
favorable clinical and imagistic response following icotinib
therapy.
To our knowledge no relevant data was published con-
cerning the c.2260A >C (K754Q) mutation. This mutation
occurred in association with an exon 19 deletion and two
other substitutions - c.2185G>A (G729R) and c.2279 T >C
(L760P). This particular sample also associated two other
silent mutations c.876G >A (V292V) and c.2361G >A
(Q787Q).
The NGS detected exon 20 insertions involved two fre-
quently affected sites - codons 771 and 774 [25]. Despite
some clinical data suggesting that at least some exon 20
insertions might associate susceptibility to certain TKI
agents [26] this mutation type is generally considered as
non-sensitizing at least to gefitinib and erlotinib [27]. Still
the c.2322G >CCACGTG (V774_C775insHV) which was
detected in our sample pool was reported as associating
partial response to chemotherapy and gefitinib [28].
In short there were five samples (~8 %) for which NGS
specific data was clinically significant although not neces-
sarily inducing management decision changes - such is the
case for two of the exon 20 inserts.
NGS also identified a rather large number of single nu-
cleotide polimorphisms (SNP). Codon 787 was most fre-
quently involved - the c.2361G>A (Q787Q) polymorphism
Table 4 Estimated workload and cost for EGFR mutation












Workload/10samples 7 h 3 h 18 h
Time to result 48–72 h 5 h 72 h
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was found in 54 samples (84.3 %). This polymorphism have
previously been reported for lung [29, 30], head and neck
[31] and colorectal adenocarcinomas [32]. Available data
attaches little physiological significance to c.2361G>A as it
seems to be mainly a germline mutation and occurrence
frequency is comparable for cancer and healthy subjects
[32]. Still there is data suggesting potential association
between lung adenocarcinoma microcystic histology pat-
tern and the presence c.2361G>A polymorphisms [33].
From the therapeutic point of view there are data suggest-
ing better response to gefitinib therapy for head and neck
cancer cells harboring heterozygous c.2361G>A [31], pos-
sibly explained by abnormal splicing [31]. For our study
sample pool there were 30 (55 %) cases exhibiting heterozy-
gous c.2361G >A. Unfortunately TKI response data is not
available for our study group and no further analysis is
possible.
To our best knowledge the other four polymorphisms
c.339C > T (Y113Y), c.876G >A (V292V), c.2430C > T
(G810G), c.2319C > T (H773H) have not been reported as
exerting any significant physiological effect.
These results support the idea of targeted approaches
such as qPCR being the first choice for low tumor content
samples at least if only one mutation hotspot is targeted.
This method is accurate, sensitive, simple and applicable
to FFPE samples [5]. Comparing the two targeted methods
alone SNaPshot showed similar results to qPCR at a sig-
nificantly smaller price per sample and somewhat higher
workload [34] but for low tumor cell content samples it
may lack sensitivity. The decision of using one method or
another should probably be made considering additional
factors - such as existing equipment, available expertise
and laboratory profile. And if in house methods are used,
a careful validation procedure should be done [35].
NGS returned comparable results to targeted methods in
terms of overall accuracy. False negative NGS results may
be diminished by using various tumor cell enrichment pro-
cedures and careful and context sensitive data interpret-
ation. In some cases alternative testing methods and/or
sample reruns may be necessary.
NGS low tumor cell content issues seems to be counter-
balanced by ensuring an adequate depth of reading cover-
age both in terms of mean read depth and also local
hotspot coverage and careful data analysis. The capacity of
detecting rare and previously unknown mutations some-
times of clinical significance makes it a valuable scientific
tool. Although rare mutations may eventually be included
in targeted panels significant cost issues may be expected.
From a strict financial perspective NGS is the most ex-
pensive technique. If the scope is widened and multiple
actionables are simultaneously considered (for example
EGFR, BRAF, KRAS) cost becomes equivalent to PCR
based methods. In order to reach the SNaPshot cost
level at least 5 to 7 different hotspots must be assessed.
Flexibility and capacity of assessing multiple targets in
one run make NGS a valuable tool taking into account
the fact that not only EGFR but other genes are emer-
ging as potential targets in lung cancer management.
Conclusion
All three methods return similar results for high tumor
content samples. Careful post analytic interpretation of re-
sults is necessary especially for low tumor content samples.
Tumor cell sample enrichment techniques may be useful.
NGS is able to generate a comprehensive mutational profile
albeit at a higher cost and workload. Result interpretation
should take into account not only general run parameters
such as mean read depth but also relative coverage and
read distribution; currently there is an acute need to define
firm recommendations/standards concerning NGS data
interpretation.
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